CA2855446C - Thienopyrimidine inhibitors of atypical protein kinase c - Google Patents
Thienopyrimidine inhibitors of atypical protein kinase c Download PDFInfo
- Publication number
- CA2855446C CA2855446C CA2855446A CA2855446A CA2855446C CA 2855446 C CA2855446 C CA 2855446C CA 2855446 A CA2855446 A CA 2855446A CA 2855446 A CA2855446 A CA 2855446A CA 2855446 C CA2855446 C CA 2855446C
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- nr22r23
- membered
- 6alkyl
- nr24c
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563310P | 2011-11-23 | 2011-11-23 | |
| US61/563,310 | 2011-11-23 | ||
| PCT/US2012/065831 WO2013078126A1 (en) | 2011-11-23 | 2012-11-19 | Thienopyrimidine inhibitors of atypical protein kinase c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2855446A1 CA2855446A1 (en) | 2013-05-30 |
| CA2855446C true CA2855446C (en) | 2021-04-20 |
Family
ID=47295200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2855446A Active CA2855446C (en) | 2011-11-23 | 2012-11-19 | Thienopyrimidine inhibitors of atypical protein kinase c |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9604994B2 (enExample) |
| EP (2) | EP3048106B1 (enExample) |
| JP (1) | JP6206926B2 (enExample) |
| CN (1) | CN104053661B (enExample) |
| AU (2) | AU2012340869B2 (enExample) |
| CA (1) | CA2855446C (enExample) |
| ES (1) | ES2575143T3 (enExample) |
| IL (1) | IL232559B (enExample) |
| IN (1) | IN2014CN04558A (enExample) |
| MX (1) | MX355088B (enExample) |
| WO (1) | WO2013078126A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN104582705A (zh) * | 2012-01-10 | 2015-04-29 | 林伯士艾瑞斯公司 | 白介素-1受体相关激酶(irak)抑制剂和其用途 |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN104902959A (zh) | 2012-07-11 | 2015-09-09 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| WO2014110114A1 (en) | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2015048281A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
| JP7114076B2 (ja) * | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| KR20180075228A (ko) * | 2016-12-26 | 2018-07-04 | 한미약품 주식회사 | 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체 |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2019119206A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| CN108658999B (zh) * | 2018-04-24 | 2021-02-05 | 温州大学 | 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法 |
| EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| CN113272308B (zh) | 2018-11-20 | 2025-03-18 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| EP3725788A1 (en) | 2019-04-15 | 2020-10-21 | Bayer AG | Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides |
| CN116410205B (zh) * | 2021-12-29 | 2024-07-05 | 上海皓元生物医药科技有限公司 | 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法 |
| CN116925098B (zh) * | 2022-04-09 | 2026-02-17 | 深圳湾实验室 | 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用 |
| WO2025085725A1 (en) * | 2023-10-20 | 2025-04-24 | Scorpion Therapeutics, Inc. | Methods for treating a p53-associated cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA782648B (en) | 1977-05-23 | 1979-06-27 | Ici Australia Ltd | The prevention,control or eradication of infestations of ixodid ticks |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| TW564247B (en) | 1999-04-08 | 2003-12-01 | Akzo Nobel Nv | Bicyclic heteraromatic compound |
| OA12050A (en) | 1999-09-30 | 2006-05-02 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles. |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| EP1329454A1 (en) | 2000-09-29 | 2003-07-23 | Nippon Soda Co., Ltd. | Thienopyrimidine compounds and their salts and process for preparation of both |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| CA2469316A1 (en) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| AR044743A1 (es) | 2002-09-26 | 2005-10-05 | Nihon Nohyaku Co Ltd | Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos, |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| AU2004247470B2 (en) | 2003-06-11 | 2009-04-23 | Xention Limited | Thienopyrimidine derivatives as potassium channel inhibitors |
| US20050187389A1 (en) | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| US7534767B2 (en) | 2004-06-15 | 2009-05-19 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
| WO2006093518A2 (en) | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
| WO2006010568A2 (de) | 2004-07-23 | 2006-02-02 | Curacyte Discovery Gmbh | Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung |
| DE102005013621A1 (de) | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
| CN101479274B (zh) | 2006-04-26 | 2013-06-12 | 霍夫曼-拉罗奇有限公司 | 药用化合物 |
| WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
| JP5500990B2 (ja) * | 2006-12-07 | 2014-05-21 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法 |
| JP2011521941A (ja) | 2008-05-30 | 2011-07-28 | ミトロジクス | Ａｎｔ−リガンド分子および生物学的アプリケ−ション |
| EP2385832B1 (en) * | 2009-01-08 | 2015-07-15 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| SI2493895T1 (sl) | 2009-10-29 | 2017-10-30 | Vectura Limited | Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze |
| AU2011239537A1 (en) * | 2010-04-16 | 2012-11-15 | Curis, Inc. | Treatment of cancers having K-ras mutations |
-
2012
- 2012-11-19 CA CA2855446A patent/CA2855446C/en active Active
- 2012-11-19 WO PCT/US2012/065831 patent/WO2013078126A1/en not_active Ceased
- 2012-11-19 CN CN201280057805.9A patent/CN104053661B/zh active Active
- 2012-11-19 ES ES12795969.0T patent/ES2575143T3/es active Active
- 2012-11-19 EP EP15196784.1A patent/EP3048106B1/en active Active
- 2012-11-19 IN IN4558CHN2014 patent/IN2014CN04558A/en unknown
- 2012-11-19 JP JP2014543517A patent/JP6206926B2/ja active Active
- 2012-11-19 AU AU2012340869A patent/AU2012340869B2/en active Active
- 2012-11-19 MX MX2014006233A patent/MX355088B/es active IP Right Grant
- 2012-11-19 EP EP12795969.0A patent/EP2782917B1/en active Active
-
2014
- 2014-05-12 IL IL232559A patent/IL232559B/en active IP Right Grant
- 2014-05-22 US US14/285,007 patent/US9604994B2/en active Active
-
2017
- 2017-01-26 US US15/417,191 patent/US10183950B2/en active Active
- 2017-06-02 AU AU2017203725A patent/AU2017203725B2/en active Active
-
2018
- 2018-12-06 US US16/212,582 patent/US10954251B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2782917A1 (en) | 2014-10-01 |
| AU2012340869B2 (en) | 2017-03-02 |
| IL232559B (en) | 2018-04-30 |
| ES2575143T3 (es) | 2016-06-24 |
| HK1202529A1 (zh) | 2015-10-02 |
| US20140323435A1 (en) | 2014-10-30 |
| MX2014006233A (es) | 2014-10-17 |
| AU2017203725A1 (en) | 2017-06-22 |
| US10183950B2 (en) | 2019-01-22 |
| IN2014CN04558A (enExample) | 2015-09-18 |
| US20190106433A1 (en) | 2019-04-11 |
| CA2855446A1 (en) | 2013-05-30 |
| NZ625447A (en) | 2015-09-25 |
| WO2013078126A1 (en) | 2013-05-30 |
| CN104053661B (zh) | 2018-06-19 |
| CN104053661A (zh) | 2014-09-17 |
| JP6206926B2 (ja) | 2017-10-04 |
| JP2014533728A (ja) | 2014-12-15 |
| MX355088B (es) | 2018-04-04 |
| US10954251B2 (en) | 2021-03-23 |
| IL232559A0 (en) | 2014-06-30 |
| EP2782917B1 (en) | 2016-03-02 |
| EP3048106B1 (en) | 2019-11-06 |
| AU2012340869A1 (en) | 2014-06-19 |
| EP3048106A1 (en) | 2016-07-27 |
| AU2017203725B2 (en) | 2019-02-28 |
| US20170158706A1 (en) | 2017-06-08 |
| US9604994B2 (en) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2855446A1 (en) | Thienopyrimidine inhibitors of atypical protein kinase c | |
| CN112778276B (zh) | 作为shp2抑制剂的化合物及其应用 | |
| US10004737B2 (en) | Fused imidazole and pyrazole derivatives as modulators of TNF activity | |
| CA2886495C (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
| US10669286B2 (en) | Fused pentacyclic imidazole derivatives as modulators of TNF activity | |
| WO2009049028A1 (en) | Pyrrolopyrimidine compounds and their use as janus kinase modulators | |
| JP2017531648A (ja) | 縮合五員環イミダゾール誘導体 | |
| US10414763B2 (en) | Azaquinazoline inhibitors of atypical protein kinase C | |
| EP2872511A1 (en) | Imidazopyrazine derivatives as modulators of tnf activity | |
| CA2692050A1 (en) | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | |
| EP2035431A1 (en) | Pharmaceutical compounds | |
| CA3161739A1 (en) | Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| CA3019245A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| CA3231988A1 (en) | Azaindazole macrocycle compound and use thereof | |
| JP2023554673A (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン | |
| NZ625447B2 (en) | Thienopyrimidine inhibitors of atypical protein kinase c | |
| HK1202529B (en) | Thienopyrimidine inhibitors of atypical protein kinase c | |
| CN122071475A (zh) | 三元稠环类衍生物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150513 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241105 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241107 |